BURLINGAME, California – Sept 10, 2024
Gilead Sciences, Inc. (Nasdaq: GILD) and Genesis Therapeutics have entered into a strategic partnership to accelerate the discovery and development of next-generation small molecule therapies. Leveraging Genesis’ AI-driven GEMS platform (Genesis Exploration of Molecular Space), the collaboration aims to optimize molecules for high-value but challenging targets, potentially leading to breakthrough treatments in multiple disease areas.
Harnessing AI for Complex Drug Discovery Challenges
Traditional drug discovery is often hindered by the complexity of certain protein targets, especially those with limited experimental data. Genesis’ GEMS AI platform integrates language models, diffusion models, and physical ML simulations to overcome these challenges, generating and refining molecular candidates with unprecedented efficiency.
“Generative AI in drug development has the potential to accelerate the discovery of molecules for challenging targets,” said Flavius Martin, M.D., EVP of Research at Gilead Sciences. “We look forward to working with Genesis to advance novel therapies that may address significant unmet patient needs.”
By combining Genesis’ expertise in AI-driven molecular optimization with Gilead’s deep experience in drug development, the collaboration aims to rapidly translate AI-generated drug candidates into clinically viable treatments.
Financial and Strategic Framework
Under the agreement:
- Genesis receives a $35 million upfront payment for work on three selected targets.
- Gilead holds the exclusive rights to develop and commercialize resulting compounds.
- Gilead has the option to nominate additional targets for a set per-target fee.
- Genesis is eligible for milestone payments across preclinical, regulatory, and commercial stages, along with tiered royalties on future net sales.
While the transaction will impact Gilead’s 2024 GAAP and non-GAAP EPS by approximately $0.02, the long-term potential for AI-driven drug discovery efficiencies could significantly enhance pipeline productivity and success rates.
Reshaping the Future of AI-Powered Biopharma
This collaboration underscores the growing role of AI in revolutionizing drug discovery. By integrating advanced machine learning with experimental biology, Gilead and Genesis are setting a new standard for AI-augmented drug development, accelerating the path from molecule to medicine.
About Genesis Therapeutics
Genesis Therapeutics is an AI-driven biotech company using its GEMS platform to design and optimize small molecule therapeutics for complex targets. Combining advanced AI, machine learning, and experimental validation, Genesis accelerates drug discovery from its headquarters in Burlingame, CA, and San Diego lab. Backed by $300M+ in funding, it is building a pipeline of breakthrough therapies.
More about news
By
